In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...
The team from Doylestown Health's Vascular Surgery is the first in the greater Philadelphia region to use the Abbott ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback